Tumor protein D52. In: Encyclopaedia of Signalling Molecules. Chen Y, Byrne JA (2017). 2nd edition. Choi S (Ed.), Springer, in press.
An Australian biobank certification scheme: a study of economic costs to participating biobanks. Ling R, Rush A, Carpenter J, Carter C, Watson P, Byrne JA, Searles A (2017). Biopreserv Biobank, in press.
PD-L1 expression in a large cohort of pediatric solid tumor patients and association with clinico-pathological features in neuroblastoma. Saletta F, Vilain RE, Gupta AK, Nagabushan S, Yuksal A, Catchpoole D, Scolyer R, Byrne JA, McCowage G (2017). JCO Precision Med. 1: 1-12.
Dropping in on the lipid droplet- tumor protein D52 (TPD52) as a new regulator and resident protein. Chen Y, Frost S, Byrne JA (2016). Adipocyte 5: 326-32.
Quality and reporting practices in an Australian cancer biobank cohort. Rush A, Byrne JA (2016). Clin Biochem 49: 492-7.
TPD52 expression increases neutral lipid storage within cultured cells. Kamili A, Roslan N, Frost S, Cantrill LC, Wang D, Della-Franca A, Bright RK, Groblewski GE, Straub BK, Hoy AJ, Chen Y, Byrne JA (2015). J Cell Sci 128: 3223-38.
Biobank classification in an Australian setting. Rush A, Christiansen JH, Farrell JP, Goode SM, Scott RJ, Spring KS, Byrne JA (2015). Biopreserv Biobank 13: 212-8.
Genetic causes of cancer predisposition in children and adolescents. Saletta F, Dalla Pozza L, Byrne JA (2015). Trans Pediatrics 4: 67-75.
Tumor protein D52 (TPD52) and cancer – oncogene understudy, or understudied oncogene? Byrne JA, Frost S, Chen Y, Bright RK (2014). Tumour Biol 35: 7369-82.
Molecular profiling of childhood cancer: biomarkers and novel therapies. Saletta F, Wadham C, Ziegler DS, Marshall GM, Haber M, McCowage G, Norris MD, Byrne JA (2014). BBA Clinical 1: 59-77